IPO - Radiopharm Theranostics Ltd

Form Type: CORRESP

Filing Date: 2024-12-11

Corporate Action: Ipo

Type: New

Accession Number: 000121390024107611

Filing Summary: Radiopharm Theranostics Limited has submitted a request for acceleration of effectiveness regarding its Registration Statement on Form F-1 that was filed on December 5, 2024. The company requests that the registration become effective at 9:00 a.m. Eastern time on December 13, 2024, or as soon as practicable thereafter. The document outlines that the effectiveness of the filing does not preclude the SEC from taking further action concerning the registration and that the company remains fully responsible for the accuracy of the disclosures made. The request was signed by Riccardo Canevari, the CEO and Managing Director of Radiopharm Theranostics Limited.

Form Type: CORRESP

Filing Date: 2024-11-25

Corporate Action: Ipo

Type: New

Accession Number: 000121390024101772

Filing Summary: Radiopharm Theranostics Limited has submitted a request to the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of their Registration Statement on Form 20-F. This request is aimed at making the Registration Statement effective at 9am Eastern Time on November 27, 2024, to facilitate the registration of their ordinary shares as represented by American Depositary Shares, leading to a planned listing on the Nasdaq Capital Market. The initial filing of the Registration Statement occurred on February 13, 2023, and the company has requested that their counsel, Rimôn Law Pty Ltd, be notified once the effectiveness is confirmed by the SEC.